Quantcast
Last updated on April 19, 2014 at 8:45 EDT

Latest Orphan drugs Stories

2012-05-22 02:26:24

SUNNYVALE, Calif., May 22, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib (formerly, PCI-32765) have been selected for oral presentations at the 17th Congress of the European Hematology Association (EHA), June 14-17, 2012 in Amsterdam, The Netherlands. The update on data presented specifically includes: 1) updated safety and efficacy data, including progression free survival, from the...

2012-05-21 22:20:47

WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., May 22, 2012 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase 3 trial evaluating Nexavar(®) (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival. An improvement in the secondary...

2012-05-17 02:25:07

SUNNYVALE, Calif., May 17, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib (formerly, PCI-32765) have been selected for oral presentations at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, 2012 in Chicago, IL. The update on data presented for the first time will specifically include: 1) safety and efficacy data from the phase II CLL single agent trial in...

2012-05-16 02:29:59

( ) ( ) ( ) SOUTH SAN FRANCISCO, Calif., May 16, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the upcoming presentations of data highlighting Nexavar® (sorafenib) tablets, Kyprolis(TM) (proposed trademark for carfilzomib) and regorafenib, a Bayer-owned compound for which Onyx will receive a royalty on global net sales. These presentations will take place at the 48th American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2012, in Chicago,...

2012-05-14 02:28:11

INDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from several molecules that make up its clinical oncology pipeline during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from June 1 - 5, 2012. Lilly Oncology has more than 30 molecules in early- and late-stage development to treat various types of cancer. The company remains committed to evaluating each of its molecules for biomarkers or genetic...

2012-05-07 06:27:04

WASHINGTON, May 7, 2012 /PRNewswire-USNewswire/ -- A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP). In study results published online today in Blood, the Journal of the American Society of Hematology (ASH), investigators at Weill Cornell Medical...

New Brain Cancer Vaccine Displays Success In Second Clinical Trial
2012-04-18 06:44:44

Connie K. Ho for RedOrbit.com On Tuesday, April 17, researchers from the University of California, San Francisco (UCSF) presented results at the American Association of Neurological Surgeons (AANS) meeting in Miami, Florida that a new brain cancer vaccine tailored to individual subjects had been successful in its second clinical trial. The vaccine is for patients who suffer from recurrent glioblastoma multiforme, a type of cancer, and it has helped extend patients´ lives. The trial...

2012-04-17 02:27:47

MONTREAL, April 17, 2012 /PRNewswire/ -The CML Society of Canada commends the Ontario government for the recent decision to add Sprycel (dasatinib) and Tasigna (nilotinib) to the list of CML (chronic myelogenous leukemia) treatments reimbursed in first line, giving patients newly diagnosed with CML more treatment options earlier.  As patient advocates for equal access to all available therapies, the CML Society of Canada feels it is important that governments are aware that it is...

2012-04-03 09:04:18

A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4. "The combination of carboplatin and nab-paclitaxel demonstrates promising efficacy with tolerable toxicity in patients with non-small cell lung cancer (NSCLC) ineligible for therapy with bevacizumab," said Gregory A....

2012-02-29 04:22:00

BRUSSELS, February 29, 2012 /PRNewswire/ -- In the news release, "'Breathtaking' Campaign Launched to Raise Awareness of Deadly Lung Disease, Pulmonary Hypertension, on Rare Disease Day" issued on 28 Feb 2012 23:01 GMT, by Pulmonary Hypertension Association Europe and Bayer HealthCare over PR Newswire, we are advised by a representative of the company that a new link fits into the following passage of text: "Footage of the 'Breathtaking' campaign events will be available at the following...